latentbrief
Back to news
Launch5d ago

GSK Teams Up With Relation Therapeutics for AI-Driven Drug Discovery

AI News1 min brief

In brief

  • GSK has joined forces with British biotech company Relation Therapeutics in a major collaboration worth up to $110 million.
    • This partnership focuses on advancing AI-assisted drug discovery by creating extensive datasets that show how human cells react to genetic changes and medications.
    • These datasets will be used to train AI models, potentially speeding up the development of new drugs.
  • The move is significant because it combines GSK's expertise in pharmaceuticals with Relation Therapeutics' advanced AI capabilities.
  • By generating large-scale biological data, the companies aim to improve the accuracy of AI predictions in drug discovery.
    • This could lead to more efficient and cost-effective ways to identify potential treatments.
    • This collaboration highlights how AI is transforming traditional drug development processes.
  • As more datasets become available, we can expect further advancements in AI-driven research, potentially leading to breakthroughs in treating complex diseases.

Terms in this brief

AI-assisted drug discovery
A method where artificial intelligence is used to help identify potential drugs by analyzing large datasets and predicting how substances might interact with biological systems. This approach can speed up the drug development process compared to traditional methods.

Read full story at AI News

More briefs